Literature DB >> 33191482

Genotype-Phenotype Associations in 72 Adults with Suspected ALPL-Associated Hypophosphatasia.

Nico Maximilian Jandl1,2, Tobias Schmidt1, Tim Rolvien1,2, Julian Stürznickel1, Konstantin Chrysostomou1, Emil von Vopelius1,2, Alexander E Volk3, Thorsten Schinke1, Christian Kubisch3, Michael Amling1, Florian Barvencik4.   

Abstract

Hypophosphatasia (HPP) is a rare inborn error of metabolism due to a decreased activity of tissue nonspecific alkaline phosphatase (TNSALP). As the onset and severity of HPP are heterogenous, it can be challenging to determine the pathogenicity of detected rare ALPL variants in symptomatic patients. We aimed to characterize patients with rare ALPL variants to propose which patients can be diagnosed with adult HPP. We included 72 patients with (1) clinical symptoms of adult HPP or positive family history and (2) low TNSALP activity and/or high pyridoxal 5'-phosphate (PLP) levels, who underwent ALPL gene sequencing. The patients were analyzed and divided into three groups depending on ALPL variant pathogenicity according to the classification of the American College of Medical Genetics and Genomics (ACMG). Reported pathogenic (n = 34 patients), rare (n = 17) and common (n = 21) ALPL variants only were found. Muscular complaints were the most frequent symptoms (> 80%), followed by bone affection (> 50%). Tooth involvement was significantly more common in patients with pathogenic or rare ALPL variants. Seven rare variants could be classified as likely pathogenic (ACMG class 4) of which five have not yet been described. Inconclusive genetic findings and less specific symptoms make diagnosis difficult in cases where adult HPP is not obvious. As not every pathogenic or rare ALPL variant leads to a manifestation of HPP, only patients with bone complications and at least one additional complication concerning teeth, muscle, central nervous and mental system, repeated low TNSALP activity and high PLP levels should be diagnosed as adult HPP if rare ALPL gene variants of ACMG class 4 or higher support the diagnosis.

Entities:  

Keywords:  ALP; Alkaline phosphatase; HPP; PLP; Pyridoxal 5′-phosphate; TNSALP

Mesh:

Substances:

Year:  2020        PMID: 33191482      PMCID: PMC7881968          DOI: 10.1007/s00223-020-00771-7

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  44 in total

1.  Rare coding variants in ALPL are associated with low serum alkaline phosphatase and low bone mineral density.

Authors:  Carrie M Nielson; Joseph M Zmuda; Amy S Carlos; Wendy J Wagoner; Emily A Larson; Eric S Orwoll; Robert F Klein
Journal:  J Bone Miner Res       Date:  2012-01       Impact factor: 6.741

2.  Genome-wide association study of hematological and biochemical traits in a Japanese population.

Authors:  Yoichiro Kamatani; Koichi Matsuda; Yukinori Okada; Michiaki Kubo; Naoya Hosono; Yataro Daigo; Yusuke Nakamura; Naoyuki Kamatani
Journal:  Nat Genet       Date:  2010-02-07       Impact factor: 38.330

3.  Discordant fetal phenotype of hypophosphatasia in two siblings.

Authors:  Satoru Ikenoue; Kei Miyakoshi; Tomohiro Ishii; Yu Sato; Toshimitsu Otani; Yohei Akiba; Yoshifumi Kasuga; Daigo Ochiai; Tadashi Matsumoto; Yosuke Ichihashi; Yohei Matsuzaki; Kanako Tachikawa; Toshimi Michigami; Gen Nishimura; Kazushige Ikeda; Tomonobu Hasegawa; Mamoru Tanaka
Journal:  Am J Med Genet A       Date:  2017-11-21       Impact factor: 2.802

Review 4.  Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment.

Authors:  Michael P Whyte
Journal:  Nat Rev Endocrinol       Date:  2016-02-19       Impact factor: 43.330

5.  Delayed transport of tissue-nonspecific alkaline phosphatase with missense mutations causing hypophosphatasia.

Authors:  Isabelle Brun-Heath; Anne-Sophie Lia-Baldini; Stéphane Maillard; Agnès Taillandier; Boris Utsch; Mark E Nunes; Jean-Louis Serre; Etienne Mornet
Journal:  Eur J Med Genet       Date:  2007-07-21       Impact factor: 2.708

6.  Different missense mutations at the tissue-nonspecific alkaline phosphatase gene locus in autosomal recessively inherited forms of mild and severe hypophosphatasia.

Authors:  P S Henthorn; M Raducha; K N Fedde; M A Lafferty; M P Whyte
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

7.  Determinants of variation in plasma alkaline phosphatase activity: a twin study.

Authors:  J B Whitfield; N G Martin
Journal:  Am J Hum Genet       Date:  1983-09       Impact factor: 11.025

8.  Large-scale in vitro functional testing and novel variant scoring via protein modeling provide insights into alkaline phosphatase activity in hypophosphatasia.

Authors:  Guillermo Del Angel; John Reynders; Christopher Negron; Thomas Steinbrecher; Etienne Mornet
Journal:  Hum Mutat       Date:  2020-03-18       Impact factor: 4.878

9.  Mild forms of hypophosphatasia mostly result from dominant negative effect of severe alleles or from compound heterozygosity for severe and moderate alleles.

Authors:  Delphine Fauvert; Isabelle Brun-Heath; Anne-Sophie Lia-Baldini; Linda Bellazi; Agnès Taillandier; Jean-Louis Serre; Philippe de Mazancourt; Etienne Mornet
Journal:  BMC Med Genet       Date:  2009-06-06       Impact factor: 2.103

10.  Can we identify individuals with an ALPL variant in adults with persistent hypophosphatasaemia?

Authors:  C Tornero; V Navarro-Compán; J A Tenorio; S García-Carazo; A Buño; I Monjo; C Plasencia-Rodriguez; J M Iturzaeta; P Lapunzina; K E Heath; A Balsa; P Aguado
Journal:  Orphanet J Rare Dis       Date:  2020-02-17       Impact factor: 4.123

View more
  9 in total

Review 1.  Proposing a clinical algorithm for better diagnosis of hypophosphatasia in resource-limiting situations.

Authors:  Sreyanko Sadhukhan; Poonam Mehta; Singh Rajender; Sushil Kumar Gupta; Naibedya Chattopadhyay
Journal:  Osteoporos Int       Date:  2022-07-01       Impact factor: 4.507

2.  Anabolic actions of parathyroid hormone in a hypophosphatasia mouse model.

Authors:  Laurie K McCauley; Nan E Hatch; Amy J Koh; Hwa Kyung Nam; Megan N Michalski; Justin Do
Journal:  Osteoporos Int       Date:  2022-07-23       Impact factor: 5.071

3.  Biochemical and clinical manifestations in adults with hypophosphatasia: a national cross-sectional study.

Authors:  Nicola Hepp; Anja Lisbeth Frederiksen; Morten Duno; Niklas Rye Jørgensen; Jens-Erik Beck Jensen
Journal:  Osteoporos Int       Date:  2022-08-19       Impact factor: 5.071

Review 4.  Hypophosphatasia: A Unique Disorder of Bone Mineralization.

Authors:  Juan Miguel Villa-Suárez; Cristina García-Fontana; Francisco Andújar-Vera; Sheila González-Salvatierra; Tomás de Haro-Muñoz; Victoria Contreras-Bolívar; Beatriz García-Fontana; Manuel Muñoz-Torres
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

5.  Prevalence of low alkaline phosphatase activity in laboratory assessment: Is hypophosphatasia an underdiagnosed disease?

Authors:  Tobias Schmidt; Constantin Schmidt; Michael Amling; Jan Kramer; Florian Barvencik
Journal:  Orphanet J Rare Dis       Date:  2021-10-28       Impact factor: 4.123

6.  Young woman with hypophosphatasia: A case report.

Authors:  Haleh Siami; Negin Parsamanesh; Shahin Besharati Kivi
Journal:  Clin Case Rep       Date:  2022-03-27

7.  Perspective on Dentoalveolar Manifestations Resulting From PHOSPHO1 Loss-of-Function: A Form of Pseudohypophosphatasia?

Authors:  Fatma F Mohamed; Michael B Chavez; Flavia Amadeu de Oliveira; Sonoko Narisawa; Colin Farquharson; José Luis Millán; Brian L Foster
Journal:  Front Dent Med       Date:  2022-02-03

8.  Biochemical, clinical and genetic characteristics in adults with persistent hypophosphatasaemia; Data from an endocrinological outpatient clinic in Denmark.

Authors:  Nicola Hepp; Anja Lisbeth Frederiksen; Morten Duno; Jakob Præst Holm; Niklas Rye Jørgensen; Jens-Erik Beck Jensen
Journal:  Bone Rep       Date:  2021-06-28

9.  Clinical, biochemical and genetic findings in adult patients with chronic hypophosphatasemia.

Authors:  V Guarnieri; F Sileri; R Indirli; G Guabello; M Longhi; G Dito; C Verdelli; S Corbetta
Journal:  J Endocrinol Invest       Date:  2021-07-02       Impact factor: 4.256

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.